Bernstein has initiated coverage on six Indian pharma stocks, with Zydus Lifesciences as its top choice. The brokerage sees strong future g...

Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Pharma major Lupin has launched its generic anti-diabetic medicine in the United States. The medicine is dapagliflozin and metformin hydroc...

Indian drug makers are launching affordable generic Semaglutide, the active ingredient in popular weight-loss drugs. Sun Pharma, Lupin, and...

Zydus Lifesciences and Lupin are joining forces. They will make a generic version of the popular weight-loss and diabetes drug semaglutide ...

Zydus Lifesciences and Lupin have joined forces to bring Semaglutide Injection to India. This medication helps manage type 2 diabetes and a...

Indian drug maker Lupin has received tentative approval from the US Food and Drug Administration (FDA) to market a generic medication used ...

US FDA's approval is for sodium sulfate, potassium sulfate and magnesium sulfate oral solution of strength 17.5 g/3.13 g/1.6 g per 6 ounces...

The company would continue to explore additional partnership opportunities in China to leverage its global portfolio including complex gene...

By leveraging this technology, Lupin expects to provide healthcare professionals with alternative solutions for delivering affordable inhal...

TB Alliance President and CEO Mel Spigelman said that partnering with Lupin -- a well-established manufacturer with experience delivering h...

Lupin said it is preparing for the launch of NaMuscla, which will occur in the initial markets of Germany and the UK in the first quarter o...

The inspection was focused on the application for certificate of suitability for the dossier of Cefaclor along with facility inspection for...

Under the terms of the agreement, Lupin will receive an up-front payment of $15 million and potential commercial milestones together with a...

Lupin has challenged the maximum retail price fixed by the country’s drug price regulator for its anti-tuberculosis brands and a new asthma...

Lupin Limited, the world's largest maker of drugs to fight tuberculosis, is considering selling its unit that markets drugs in India, said ...